Regeneron reported its fourth quarter 2018 GAAP net income at $820 million, a 371% increase from the fourth quarter 2017 GAAP net income.
For the full year, Regeneron reported $2.4 billion in GAAP net income, a 104% increase over the 2017 full year.
Net sales of Eylea (aflibercept) injection in the U.S. increased 11% to $1.08 billion in the fourth quarter of 2018 vs. $975 million, an increase of 11%, in the same quarter of 2017.
For the full year, Eylea net product sales were $4.08 billion compared with $3.7 (Read more...)
Uncategorized